Drug Details
General Information of the Drug (ID: DR3634) | ||||
---|---|---|---|---|
Name |
Duloxetine
|
|||
Synonyms |
duloxetine; 116539-59-4; (S)-Duloxetine; Cymbalta; Yentreve; (S)-N-Methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine; LY 248686; 136434-34-9; UNII-O5TNM5N07U; Ariclaim; Xeristar; LY248686; Yentreve (TN); (3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine; O5TNM5N07U; 2-Thiophenepropanamine, N-methyl-gamma-(1-naphthalenyloxy)-, (gammaS)-; N-Methyl-gama-(1-naphthalenyloxy)-2-thiophenepropanamine; CHEBI:36795; (3S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amine; MFCD06801358; LY-248686; methyl[(3S)-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propyl]amine; (3s)-N-Methyl-3-(Naphthalen-1-Yloxy)-3-(Thiophen-2-Yl)propan-1-Amine; Duloxetine [INN:BAN]; Duloxetine (INN); SMR000449282; HSDB 7368; NCGC00164559-01; Duloxetine Boehringer Ingelheim; (S)-N-Methyl-gamma-(1-naphthalenyloxy)-2-thiophenepropanamine; 29E; CPD000449282; SCHEMBL8291; CHEMBL1175; GTPL202; cc-636; MLS000758267; MLS001423946; (S)-Duloxetine;LY248686; DTXSID6048385; BDBM84745; HMS2051I05; HMS3886K11; HY-B0161; ZINC1536779; (3S)-N-methyl-3-(naphthalen-1-yloxy)-3-(2-thienyl)propan-1-amine; 2-Thiophenepropanamine, N-methyl-gamma-(1-naphthalenyloxy)-, (S)-; ANW-63714; PDSP1_000969; PDSP1_001385; PDSP2_000953; PDSP2_001369; s5071; AKOS015851058; CCG-100763; CM14423; DB00476; NC00013; SB19317; VA11973; NCGC00164559-02; NCGC00164559-04; AC-15704; AS-35259; SBI-0206832.P001; CAS_136434-34-9; D07880; AB00639911-13; AB00639911_15; AB00639911_16; 539D594; Q411932; J-003455; J-523680; (+)-(S)-N-Methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamin; (S)-(+)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine; (S)-N-methyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propanamine; (3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-yl-propan-1 amine; (3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-yl-propan-1-amine; (3s)-n-methyl-3-naphthalen-1-yloxy-3-thiophen-2-yl-propan-1amine; (S)-(+)-N-methyl-3-(1-naphthaleneoxy)-3-(2-thienyl)propanamine
Click to Show/Hide
|
|||
Molecular Type |
Small molecule
|
|||
Disease | Depression [ICD-11: 6A70-6A71] | Approved | [1] | |
Structure |
![]() |
Click to Download Mol2D MOL |
||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
Formula |
C18H19NOS
|
|||
PubChem CID | ||||
Canonical SMILES |
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32
|
|||
InChI |
1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m0/s1
|
|||
InChIKey |
ZEUITGRIYCTCEM-KRWDZBQOSA-N
|
|||
CAS Number |
CAS 116539-59-4
|
|||
ChEBI ID | ||||
TTD Drug ID | ||||
DrugBank ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Decrease the Adverse Effect of This Drug | ||||||
Phloretin | Prunus armeniaca | Click to Show/Hide the Molecular Data of This NP | ||||
Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
In-vivo Model | Diabetic neuropathy (DN) rat models were used in this study. | |||||
Experimental
Result(s) |
DX augmented the DM metabolic disturbance and hepatic dysfunction, however, PH effectively amended these disorders. The low-dose combination of both, had the merits of both medications, with the alleviation of their disadvantages. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Norepinephrine transporter (NET) | Molecule Info | [3] | |
Serotonin transporter (SERT) | Molecule Info | [3] | ||
KEGG Pathway | Serotonergic synapse | Click to Show/Hide | ||
NetPath Pathway | TCR Signaling Pathway | Click to Show/Hide | ||
Panther Pathway | 5HT1 type receptor mediated signaling pathway | Click to Show/Hide | ||
2 | 5HT2 type receptor mediated signaling pathway | |||
3 | 5HT3 type receptor mediated signaling pathway | |||
4 | 5HT4 type receptor mediated signaling pathway | |||
5 | Adrenaline and noradrenaline biosynthesis | |||
Reactome | Na+/Cl- dependent neurotransmitter transporters | Click to Show/Hide | ||
WikiPathways | Monoamine Transport | Click to Show/Hide | ||
2 | SIDS Susceptibility Pathways | |||
3 | NRF2 pathway | |||
4 | Synaptic Vesicle Pathway | |||
5 | Serotonin Transporter Activity | |||
6 | Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds |
